MCID: GLC008
MIFTS: 40

Glucose Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 15 17
Glucose Metabolism Disorders 43 71
Disorder of Glucose Metabolism 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4194
MeSH 43 D044882
NCIt 49 C53655
SNOMED-CT 67 126877002
UMLS 71 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and fatty liver disease. An important gene associated with Glucose Metabolism Disease is PINK1-AS (PINK1 Antisense RNA), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Insulin glargine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney.

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 403)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 33.1 MIR223 MIR17 MIR155 MIR146A MIR140 MIR126
2 fatty liver disease 31.5 MIR21 MIR155 INS ALB
3 non-alcoholic fatty liver disease 31.4 MIR21 MIR199A1 MIR17 MIR155 MIR140 MIR126
4 coronary heart disease 1 31.3 MIR17 MIR155 MIR140 MIR126 INS
5 diabetes mellitus, ketosis-prone 31.2 INS GCG ALB
6 hepatocellular carcinoma 31.2 SERPINA3 MIR423 MIR29A MIR223 MIR21 MIR199A1
7 hyperglycemia 31.1 MIR126 INS GCG ALB
8 myeloma, multiple 31.0 SERPINA3 MIR28 MIR21 MIR199A1 MIR17 MIR142
9 acute cystitis 31.0 SERPINA3 INS H2AC18 CCR6 ALB
10 diabetes mellitus, type i 31.0 MIR21 INS ICOSLG H2AC18 GCG CCR6
11 prediabetes syndrome 31.0 SERPINA3 MIR126 INS GCG ALB
12 pulmonary disease, chronic obstructive 31.0 SERPINA3 MIR423 MIR28 MIR223 MIR21 MIR199A1
13 placenta disease 31.0 SERPINA3 MIR199A1 MIR146A INS H2AC18
14 microvascular complications of diabetes 5 31.0 MIR21 MIR126 INS H2AC18 ALB
15 pancreatic cancer 31.0 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR155
16 diabetes mellitus, noninsulin-dependent 30.9 SERPINA3 MIR423 MIR29A MIR28 MIR21 MIR199A1
17 lipid metabolism disorder 30.9 MIR21 MIR126 INS H2AC18
18 arteries, anomalies of 30.9 SERPINA3 MIR423 MIR28 MIR223 MIR21 MIR199A1
19 lipoprotein quantitative trait locus 30.9 MIR223 MIR21 MIR199A1 MIR146A MIR126 ALB
20 arteriosclerosis 30.9 MIR21 MIR155 MIR142 MIR126 INS
21 body mass index quantitative trait locus 11 30.9 SERPINA3 MIR423 MIR29A MIR28 MIR223 MIR21
22 esophageal cancer 30.9 MIR423 MIR28 MIR223 MIR21 MIR199A1 MIR155
23 microvascular complications of diabetes 3 30.9 MIR21 INS ALB
24 pancreatitis 30.8 MIR21 INS GCG ALB
25 macular degeneration, age-related, 1 30.8 SERPINA3 INS H2AC18 CCR6 ALB
26 respiratory failure 30.6 SERPINA3 H2AC18 CCR6 ALB
27 hypoglycemia 11.2
28 triosephosphate isomerase deficiency 11.2
29 bacterial infectious disease 10.9 SERPINA3 MIR155 ICOSLG H2AC18 CCR6
30 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 INS
31 central nervous system cancer 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
32 peripheral nervous system disease 10.9 SERPINA3 MIR21 MIR146A MIR142 MIR126 INS
33 thyroid gland disease 10.9 SERPINA3 MIR199A1 MIR17 MIR142 INS ICOSLG
34 lipid storage disease 10.9 SERPINA3 MIR21 MIR199A1 MIR155 MIR142 INS
35 mouth disease 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
36 extrinsic cardiomyopathy 10.9 SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR142
37 heart valve disease 10.9 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
38 cell type benign neoplasm 10.9 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR142
39 muscular disease 10.9 SERPINA3 MIR199A1 MIR142 MIR140 MIR126 INS
40 bile duct adenocarcinoma 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
41 autonomic nervous system neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
42 peripheral nervous system neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
43 muscle tissue disease 10.9 SERPINA3 MIR199A1 MIR142 MIR126 INS ICOSLG
44 heart conduction disease 10.9 SERPINA3 MIR423 MIR21 MIR199A1 MIR146A MIR142
45 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
46 inherited metabolic disorder 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
47 ovary epithelial cancer 10.9 SERPINA3 MIR21 MIR199A1 MIR17 ICOSLG H2AC18
48 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 ICOSLG H2AC18
49 primary bacterial infectious disease 10.9 SERPINA3 MIR223 MIR21 MIR155 MIR142 ICOSLG
50 autosomal genetic disease 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR146A MIR142

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Lopinavir Approved Phase 4 192725-17-0 92727
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Zidovudine Approved Phase 4 30516-87-1 35370
6
Sertraline Approved Phase 4 79617-96-2 68617
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
9
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
10
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
11 Neurotransmitter Agents Phase 4
12 Antiviral Agents Phase 4
13 Psychotropic Drugs Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Reverse Transcriptase Inhibitors Phase 4
16 Anti-HIV Agents Phase 4
17 Lamivudine, zidovudine drug combination Phase 4
18 Anti-Retroviral Agents Phase 4
19 Cytochrome P-450 CYP3A Inhibitors Phase 4
20 Black Currant Phase 4
21 Antidepressive Agents Phase 4
22 Serotonin Uptake Inhibitors Phase 4
23 Insulin degludec, insulin aspart drug combination Phase 4
24 Insulin, Long-Acting Phase 4
25 Sodium Chloride Symporter Inhibitors Phase 4
26 diuretics Phase 4
27 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
28 Sodium-Glucose Transporter 2 Inhibitors Phase 4
29 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
30 Pharmaceutical Solutions Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
32
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
33
Glimepiride Approved Phase 3 93479-97-1 3476
34
Gliclazide Approved Phase 3 21187-98-4 3475
35
Glyburide Approved Phase 3 10238-21-8 3488
36
Liraglutide Approved Phase 3 204656-20-2 44147092
37
Alogliptin Approved Phase 3 850649-61-5 11450633
38
Ramipril Approved Phase 3 87333-19-5 5362129
39
Dulaglutide Approved, Investigational Phase 3 923950-08-7
40
Calcium carbonate Approved, Investigational Phase 3 471-34-1
41
Linagliptin Approved Phase 3 668270-12-0 10096344
42
Fenofibrate Approved Phase 3 49562-28-9 3339
43
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
44
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
45 Nutmeg Approved Phase 3
46
Bupropion Approved Phase 3 34911-55-2, 34841-39-9 444
47 Cardiac Glycosides Phase 3
48 Glycoside Hydrolase Inhibitors Phase 3
49 Immunologic Factors Phase 3
50 Immunosuppressive Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements Completed NCT00483769 Phase 4 Glargine
2 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
3 A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism Completed NCT00192621 Phase 4 Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr])
4 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
5 Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent Completed NCT00834652 Phase 4 Sertraline;Metformin
6 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
7 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Recruiting NCT02744976 Phase 4 Metformin
8 Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol Active, not recruiting NCT04242758 Phase 4 Dapagliflozin 10 MG;Hydrochlorothiazide 12.5mg
9 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
10 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Terminated NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
11 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
12 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia. Completed NCT00349128 Phase 2, Phase 3 fenofibrate and metformin combination (drug)
13 An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia Completed NCT00348725 Phase 3 fenofibrate and metformin fixed combination (drug)
14 Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) Completed NCT00221156 Phase 3 Acarbose
15 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00736879 Phase 3 Dapagliflozin;Placebo
16 An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting Completed NCT01340768 Phase 3 Sitagliptin;Sulfonylurea;Metformin
17 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT01841697 Phase 3 Omarigliptin;Sitagliptin;Placebo to omarigliptin;Placebo to Sitagliptin;Open-label Metformin;Open-label Glimepiride
18 A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00859898 Phase 3 Dapagliflozin;Metformin XR;Metformin XR;dapagliflozin matching Placebo;metformin HCl Modified Release matching Placebo
19 A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin. Completed NCT00362323 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Metformin
20 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome Completed NCT00968708 Phase 3 Alogliptin;Placebo
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Completed NCT01137474 Phase 3 Dapagliflozin;Placebo-matching dapagliflozin
23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
24 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Completed NCT01814748 Phase 3 Omarigliptin;Placebo to omarigliptin;Metformin
25 Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia Completed NCT02092896 Phase 3 Liraglutide;Placebo;Liraglutide;Placebo
26 The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial Completed NCT00095654 Phase 3 Ramipril;Rosiglitazone
27 The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) Recruiting NCT04255433 Phase 3 Tirzepatide;Dulaglutide
28 Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) Active, not recruiting NCT03730662 Phase 3 Tirzepatide;Insulin Glargine
29 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Not yet recruiting NCT04371978 Phase 3 Linagliptin 5 MG
30 A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Terminated NCT00361868 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Rosiglitazone
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR Terminated NCT01601704 Phase 3 NB32;PBO
32 Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation Terminated NCT00935766 Phase 3 Omega-3;Placebo
33 Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose. Unknown status NCT02102737 Phase 2 6-DIG
34 Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes Completed NCT01001104 Phase 2 LY2189265;Placebo
35 A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults Completed NCT00600067 Phase 2 Phentermine/Topiramate;Placebo
36 A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus Completed NCT02004886 Phase 2 MK-0893;Metformin;Placebo;Placebo
37 Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes Completed NCT02464033 Phase 2 GAD-Alum;Vitamin D;Etanercept
38 The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device Completed NCT01073566 Phase 2
39 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
40 Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans Completed NCT01354977 Phase 2 Resveratrol
41 Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation Completed NCT01354964 Phase 2 Vitamin D;Placebo
42 A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia Completed NCT02771574 Phase 2 Exendin (9-39)
43 A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study. Completed NCT01261494 Phase 2 GFT505 80mg;Placebo
44 Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen Completed NCT01785108 Phase 2 Vitamin D;Ibuprofen
45 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT03371355 Phase 2 ISIS 703802;Placebo
46 Acute Metabolic Effects of Melatonin Treatment Completed NCT03204877 Phase 1, Phase 2 Melatonin
47 Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes Completed NCT01935804 Phase 2 Pioglitazone;Metformin
48 Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus Completed NCT02644759 Phase 1, Phase 2
49 A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients Completed NCT02733588 Phase 2 G-Pump™ (glucagon infusion)
50 An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes Completed NCT01778348 Phase 2

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

MalaCards organs/tissues related to Glucose Metabolism Disease:

40
Liver, Heart, Kidney, Endothelial, Lymph Node, Testes, Bone

Publications for Glucose Metabolism Disease

Articles related to Glucose Metabolism Disease:

(show top 50) (show all 211)
# Title Authors PMID Year
1
High glucose level as a modifier factor in CMT1A patients. 61
32347995 2020
2
Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. 61
31721134 2020
3
Respiratory Inflammation and Short-Term Ambient Air Pollution Exposures in Adult Beijing Residents with and without Prediabetes: A Panel Study. 61
32484751 2020
4
Evaluation of Apple Pomace Flour Obtained Industrially by Dehydration as a Source of Biomolecules with Antioxidant, Antidiabetic and Antiobesity Effects. 61
32408574 2020
5
Prevalence of glucose metabolism disorders in a cohort of children and adolescents with obesity. 61
32383231 2020
6
Glucose metabolism disorders in children with refractory nephrotic syndrome. 61
31950245 2020
7
Depression, changes in peripheral blood cell count, and changes in selected biochemical parameters related to lead concentration in whole blood (Pb-B) of women in the menopausal period. 61
32289550 2020
8
Association of Lipid Parameters with the Risk of Chronic Kidney Disease: A Longitudinal Study Based on Populations in Southern China. 61
32184645 2020
9
Evaluation of skin autofluorescence as a surrogate of advanced glycation end products accumulation in children and adolescents with normal haemoglobin A1c values. 61
32418416 2020
10
Downregulated ABHD5 Aggravates Insulin Resistance of Trophoblast Cells During Gestational Diabetes Mellitus. 61
32046372 2020
11
Prevalence of undiagnosed glucose intolerance and type 2 diabetes in patients with moderate-to-severe obstructive sleep apnea syndrome. 61
31838624 2019
12
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study. 61
31829160 2019
13
High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling. 61
31634780 2019
14
Agenesis of the dorsal pancreas presenting with diabetic ketoacidosis - a case report and literature review. 61
31711495 2019
15
Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice. 61
31089202 2019
16
Protective effects of melatonin on sepsis-induced liver injury and dysregulation of gluconeogenesis in rats through activating SIRT1/STAT3 pathway. 61
31234024 2019
17
Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice. 61
31054103 2019
18
Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. 61
31144451 2019
19
Extensive metabolic remodeling after limiting mitochondrial lipid burden is consistent with an improved metabolic health profile. 61
31097541 2019
20
Low intake of digestible carbohydrates ameliorates duodenal absorption of carbohydrates in mice with glucose metabolism disorders induced by artificial sweeteners. 61
30953347 2019
21
[Bone microarchitecture and other body composition parameters in patients with overweight or obesity grouped by glucose metabolism disorders]. 61
31192689 2019
22
Glucose Metabolism Abnormalities in Heart Failure Patients: Insights and Prognostic Relevance. 61
31079691 2019
23
Prevention of Cardiovascular Diseases in Children and Adolescents. 61
31041682 2019
24
Adipose Tissue Mediates Associations of Birth Weight with Glucose Metabolism Disorders in Children. 61
30811103 2019
25
Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center. 61
31137898 2019
26
H2S promotes a glycometabolism disorder by disturbing the Th1/Th2 balance during LPS-induced inflammation in the skeletal muscles of chickens. 61
30703651 2019
27
Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. 61
31108989 2019
28
The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. 61
30945387 2019
29
Ammonia exposure induced abnormal expression of cytokines and heat shock proteins via glucose metabolism disorders in chicken neutrophils. 61
30767103 2019
30
Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. 61
30674738 2019
31
The ratio of fasting plasma glucose to hemoglobin A1c as a predictor of all-cause mortality in individuals with normal glucose levels: The Jichi Medical School cohort study. 61
31263559 2019
32
Influence of Maternal Inulin-Type Prebiotic Intervention on Glucose Metabolism and Gut Microbiota in the Offspring of C57BL Mice. 61
31632351 2019
33
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression. 61
30063256 2019
34
Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study. 61
31686868 2019
35
Potential role of liver enzyme levels as predictive markers of glucose metabolism disorders in a Tunisian population. 61
29527933 2018
36
Prediction of Glucose Metabolism Disorder Risk Using a Machine Learning Algorithm: Pilot Study. 61
30478026 2018
37
Maternal lipopolysaccharide exposure results in glucose metabolism disorders and sex hormone imbalance in male offspring. 61
29614340 2018
38
Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats. 61
29209957 2018
39
Chlorogenic Acid Targeting of the AKT PH Domain Activates AKT/GSK3β/FOXO1 Signaling and Improves Glucose Metabolism. 61
30249058 2018
40
Dynapenic obesity as an associated factor to lipid and glucose metabolism disorders and metabolic syndrome in older adults - Findings from SABE Study. 61
28647293 2018
41
Diabetes mellitus and insulin resistance associate with left ventricular shape and torsion by cardiovascular magnetic resonance imaging in asymptomatic individuals from the multi-ethnic study of atherosclerosis. 61
30064457 2018
42
Pretransplantation Oral Glucose Tolerance Test Can Prevent Posttransplant Diabetes Mellitus After Renal Transplantation: Preliminary Study. 61
30056899 2018
43
Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. 61
29279271 2018
44
Impact of Glucose Metabolism Disorders on IGF-1 Levels in Patients with Acromegaly. 61
29642245 2018
45
Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: Is glycated haemoglobin useful? Data from the prospective REHABDIAB study. 61
29370710 2018
46
Maternal educational level and the risk of persistent post-partum glucose metabolism disorders in women with gestational diabetes mellitus. 61
29288374 2018
47
Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. 61
29229354 2018
48
Aberrant expression of miR-451a contributes to 1,2-dichloroethane-induced hepatic glycerol gluconeogenesis disorder by inhibiting glycerol kinase expression in NIH Swiss mice. 61
28960355 2018
49
Heart in Acromegaly: The Echocardiographic Characteristics of Patients Diagnosed with Acromegaly in Various Stages of the Disease. 61
30123265 2018
50
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. 61
29227477 2018

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR423 MIR29A MIR28 MIR223 MIR21 MIR199A1

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.53 SERPINA3 MIR423 MIR29A MIR28 MIR223 MIR21
2 extracellular vesicle GO:1903561 9.26 MIR29A MIR21 MIR17 MIR126

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.96 MIR29A MIR21 MIR17 MIR155 MIR146A
2 cellular response to lipopolysaccharide GO:0071222 9.89 MIR21 MIR17 MIR146A MIR140
3 positive regulation of angiogenesis GO:0045766 9.87 MIR29A MIR21 MIR199A1 MIR126
4 positive regulation of gene expression GO:0010628 9.87 MIR29A MIR223 MIR21 MIR155 MIR146A MIR140
5 positive regulation of inflammatory response GO:0050729 9.83 MIR21 MIR155 MIR126
6 positive regulation of protein kinase B signaling GO:0051897 9.83 MIR29A MIR21 MIR199A1 MIR126 INS
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 MIR21 MIR126 INS
8 positive regulation of endothelial cell migration GO:0010595 9.77 MIR29A MIR21 MIR199A1
9 negative regulation of inflammatory response GO:0050728 9.77 MIR223 MIR155 MIR146A MIR142 MIR126
10 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR199A1 MIR155 MIR146A
11 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.72 MIR223 MIR21 MIR146A
12 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.71 MIR155 MIR146A MIR140
13 positive regulation of activated T cell proliferation GO:0042104 9.7 MIR21 MIR155 ICOSLG
14 positive regulation of vascular endothelial cell proliferation GO:1905564 9.69 MIR29A MIR21 MIR126
15 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.67 MIR21 MIR146A MIR126
16 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.66 MIR17 MIR155
17 positive regulation of connective tissue replacement GO:1905205 9.66 MIR199A1 MIR155
18 negative regulation of toll-like receptor 4 signaling pathway GO:0034144 9.65 MIR146A MIR140
19 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR223 MIR21 MIR140
20 cellular response to hypoxia GO:0071456 9.65 MIR17 MIR155 MIR146A MIR140 MIR126
21 negative regulation of matrix metallopeptidase secretion GO:1904465 9.64 MIR199A1 MIR146A
22 positive regulation of microglial cell activation GO:1903980 9.64 MIR155 MIR142
23 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.63 MIR155 MIR146A
24 negative regulation of interleukin-8 production GO:0032717 9.63 MIR155 MIR146A
25 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.63 MIR199A1 MIR17 MIR155
26 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.62 MIR155 MIR146A
27 positive regulation of metalloendopeptidase activity GO:1904685 9.62 MIR21 MIR17
28 negative regulation of regulatory T cell differentiation GO:0045590 9.61 MIR21 MIR155
29 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR21 MIR17
30 negative regulation of necrotic cell death GO:0060547 9.58 MIR223 MIR155
31 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17 MIR155
32 negative regulation of vascular endothelial growth factor production GO:1904046 9.46 MIR199A1 MIR17 MIR146A MIR140
33 miRNA mediated inhibition of translation GO:0035278 9.43 MIR29A MIR28 MIR21 MIR17 MIR155 MIR146A
34 gene silencing by miRNA GO:0035195 9.4 MIR423 MIR29A MIR28 MIR223 MIR21 MIR199A1

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR423 MIR29A MIR28 MIR223 MIR21 MIR199A1

Sources for Glucose Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....